NCT06246357View on ClinicalTrials.gov

Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 23, 2024

Primary Completion Date

December 1, 2027

Study Completion Date

April 1, 2028

Conditions
HyperaldosteronismHypercortisolismCushing s Syndrome
Interventions
DRUG

[68Ga]Ga-PentixaFor

\[68Ga\]Ga-PentixaFor will be injected intravenously approximately 60 minutes prior to scanning at a dose of 150 +/- 50 MBq (4 mCi +/- 1.4).

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH